Literature DB >> 11679962

Transforming growth factor beta and activin tonically inhibit DNA synthesis in the rat liver.

T Ichikawa1, Y Q Zhang, K Kogure, Y Hasegawa, H Takagi, M Mori, I Kojima.   

Abstract

The present study was conducted to assess the role of transforming growth factor beta (TGF-beta) and activin(s) in the regulation of the mass of the liver. To this end, we eliminated TGF-beta or activin signaling in intact rat liver by adenovirus-mediated transfer of the gene encoding truncated type II TGF-beta receptor (AdextTR) or truncated type II activin receptor (AdextAR). In intact rat liver that received a single application of either AdextTR or AdextAR via the portal vein, DNA synthesis as assessed by bromodeoxy uridine (BrdU) labeling was induced. In AdextTR- or AdextAR-treated rats, nuclear labeling was significantly higher than that in AdexLacZ, adenovirus vector encoding Escherichia coli beta-galactosidase gene, or saline-treated rats at 3, 5, 7, and 9 days of infusion. The peak of the BrdU labeling was observed after 7 days of infusion and the labeling decreased thereafter. Apoptosis of hepatocytes, assessed by the terminal deoxynucleotidyl transferase (TdT)-mediated, dUTP-biotin nick-end labeling method was detected after 9 days of infusion. Immunoreactivity of TGF-beta and activin A increased in the liver after the blockade of the activin or TGF-beta signaling. TGF-beta and activin A may have been up-regulated when the action of these ligands was blocked. These results indicate that blockade of the action of either TGF-beta or activin leads to the initiation of DNA synthesis in intact liver. TGF-beta and activin tonically inhibit hepatocyte growth even in intact liver and may play a critical role in the maintenance of constant liver mass.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11679962     DOI: 10.1053/jhep.2001.29132

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  23 in total

1.  Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy.

Authors:  Kevin J Morine; Lawrence T Bish; Joshua T Selsby; Jeffery A Gazzara; Klara Pendrak; Meg M Sleeper; Elisabeth R Barton; Se-Jin Lee; H Lee Sweeney
Journal:  Muscle Nerve       Date:  2010-11       Impact factor: 3.217

2.  Combined systemic elimination of MET and epidermal growth factor receptor signaling completely abolishes liver regeneration and leads to liver decompensation.

Authors:  Shirish Paranjpe; William C Bowen; Wendy M Mars; Anne Orr; Meagan M Haynes; Marie C DeFrances; Silvia Liu; George C Tseng; Anastasia Tsagianni; George K Michalopoulos
Journal:  Hepatology       Date:  2016-10-01       Impact factor: 17.425

Review 3.  Liver regeneration.

Authors:  George K Michalopoulos
Journal:  J Cell Physiol       Date:  2007-11       Impact factor: 6.384

Review 4.  Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas.

Authors:  George K Michalopoulos
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

Review 5.  Liver regeneration: biological and pathological mechanisms and implications.

Authors:  George K Michalopoulos; Bharat Bhushan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-08-06       Impact factor: 46.802

6.  Effect of transforming growth factor-beta1 on human intrahepatic cholangiocarcinoma cell growth.

Authors:  Tetsuya Shimizu; Shigeki Yokomuro; Yoshiaki Mizuguchi; Yutaka Kawahigashi; Yasuo Arima; Nobuhiko Taniai; Yasuhiro Mamada; Hiroshi Yoshida; Koho Akimaru; Takashi Tajiri
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

7.  Impaired liver regeneration in Ldlr-/- mice is associated with an altered hepatic profile of cytokines, growth factors, and lipids.

Authors:  Montse Pauta; Noemi Rotllan; Frances Vales; Ana Fernandez-Hernando; Ryan M Allen; David A Ford; Montserrat Marí; Wladimiro Jiménez; Angel Baldán; Manuel Morales-Ruiz; Carlos Fernández-Hernando
Journal:  J Hepatol       Date:  2013-05-24       Impact factor: 25.083

Review 8.  Activins and activin antagonists in hepatocellular carcinoma.

Authors:  Alev Deli; Emanuel Kreidl; Stefan Santifaller; Barbara Trotter; Katja Seir; Walter Berger; Rolf Schulte-Hermann; Chantal Rodgarkia-Dara; Michael Grusch
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

Review 9.  Liver regeneration.

Authors:  Shennen A Mao; Jaime M Glorioso; Scott L Nyberg
Journal:  Transl Res       Date:  2014-01-16       Impact factor: 7.012

10.  Determining the effect of transforming growth factor-β1 on cdk4 and p27 in gastric cancer and cholangiocarcinoma.

Authors:  Sung Ryol Lee; Jae Wook Shin; Hyung Ook Kim; Byung Ho Son; Chang Hak Yoo; Jun Ho Shin
Journal:  Oncol Lett       Date:  2012-11-13       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.